The novel thymidylate synthase inhibitor trifluorothymidine (TFT) has been reported to enhance TRAIL-induced apoptosis in NSCLC cells by sensitizing the apoptotic machinery at different levels in the TRAIL pathway (154). Here, TNFSF10 is linked to non-small cell lung carcinoma.